Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer

[1]  Helen H. W. Chen,et al.  Hypoxia-inducible factor-1α correlates with MET and metastasis in node-negative breast cancer , 2007, Breast Cancer Research and Treatment.

[2]  G. Panayotou,et al.  Identification of MAPK Phosphorylation Sites and Their Role in the Localization and Activity of Hypoxia-inducible Factor-1α* , 2006, Journal of Biological Chemistry.

[3]  Max Costa,et al.  Hypoxia-Inducible Factor-1 (HIF-1) , 2006, Molecular Pharmacology.

[4]  R. Millikan,et al.  CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance , 2006, Clinical Cancer Research.

[5]  C. Sotiriou,et al.  What clinicians need to know about antioestrogen resistance in breast cancer therapy. , 2006, European journal of cancer.

[6]  J. Geraghty,et al.  Oncological implications of hypoxia inducible factor-1α (HIF-1α) expression , 2006 .

[7]  J. Simons,et al.  Hypoxia-inducible factor-1 in human breast and prostate cancer. , 2006, Endocrine-related cancer.

[8]  Manuela Milani,et al.  Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer , 2006, Clinical Cancer Research.

[9]  Young Joo Lee,et al.  Hypoxic activation of unoccupied estrogen-receptor-alpha is mediated by hypoxia-inducible factor-1 alpha , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[11]  K. Jirström,et al.  Hypoxia inducible factor‐1α is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response , 2006, International journal of cancer.

[12]  K. Neurath,et al.  Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation , 2006, Oncogene.

[13]  M. Schindl,et al.  Hypoxia inducible factor-1α correlates with VEGF-C expression and lymphangiogenesis in breast cancer , 2006, Breast Cancer Research and Treatment.

[14]  R. Schiff,et al.  Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. , 2005, Breast.

[15]  Daniel F Hayes,et al.  Prognostic and predictive factors revisited. , 2005, Breast.

[16]  U. Lendahl,et al.  Hypoxia requires notch signaling to maintain the undifferentiated cell state. , 2005, Developmental cell.

[17]  F. Bertucci,et al.  How to best classify breast cancer: conventional and novel classifications (review). , 2005, International journal of oncology.

[18]  E. van Marck,et al.  Angiogenesis and hypoxia in lymph node metastases is predicted by the angiogenesis and hypoxia in the primary tumour in patients with breast cancer , 2005, British Journal of Cancer.

[19]  P. Bonnier,et al.  Overexpression of hypoxia‐inducible factor HIF‐1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients , 2005, International journal of cancer.

[20]  E. Fredlund,et al.  Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors. , 2005, Seminars in cell & developmental biology.

[21]  Youngjoo Lee,et al.  Cobalt Chloride-Induced Estrogen Receptor α Down-Regulation Involves Hypoxia-Inducible Factor-1α in MCF-7 Human Breast Cancer Cells , 2005 .

[22]  A. Mercurio,et al.  Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin. , 2005, Cancer research.

[23]  M. Ringnér,et al.  Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer. , 2005 .

[24]  A. Harris,et al.  HIF-2alpha expression in human fetal paraganglia and neuroblastoma: relation to sympathetic differentiation, glucose deficiency, and hypoxia. , 2005, Experimental cell research.

[25]  A. Harris,et al.  Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer , 2005, Journal of Clinical Pathology.

[26]  L. Murphy,et al.  Intermittent Hypoxia Induces Proteasome-Dependent Down-Regulation of Estrogen Receptor α in Human Breast Carcinoma , 2004, Clinical Cancer Research.

[27]  Kyu-Won Kim,et al.  Sumoylation increases HIF-1α stability and its transcriptional activity , 2004 .

[28]  Peter Vaupel,et al.  The role of hypoxia-induced factors in tumor progression. , 2004, The oncologist.

[29]  J. Palazzo,et al.  The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast , 2004, Cancer.

[30]  G. Paine-Murrieta,et al.  Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1α , 2004, Molecular Cancer Therapeutics.

[31]  M. Hiraoka,et al.  Tumor hypoxia: A target for selective cancer therapy , 2003, Cancer science.

[32]  G. Powis,et al.  Hypoxia inducible factor as a cancer drug target. , 2003, Current cancer drug targets.

[33]  A. Giaccia,et al.  HIF-1 as a target for drug development , 2003, Nature Reviews Drug Discovery.

[34]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[35]  J. Pouysségur,et al.  HIF prolyl‐hydroxylase 2 is the key oxygen sensor setting low steady‐state levels of HIF‐1α in normoxia , 2003, The EMBO journal.

[36]  I. Yasinska,et al.  S‐nitrosation of Cys‐800 of HIF‐1α protein activates its interaction with p300 and stimulates its transcriptional activity , 2003, FEBS letters.

[37]  M. Miyazaki,et al.  Comedonecrosis is an unfavorable marker in node‐negative invasive breast carcinoma , 2003, Pathology international.

[38]  G. Landberg,et al.  Regional cyclin D1 overexpression or hypoxia correlate inversely with heterogeneous oestrogen receptor-alpha expression in human breast cancer. , 2003, In vivo.

[39]  G. Landberg,et al.  Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. , 2003, Cancer research.

[40]  P. V. van Diest,et al.  Levels of hypoxia‐inducible factor‐1α independently predict prognosis in patients with lymph node negative breast carcinoma , 2003, Cancer.

[41]  G. Booker,et al.  The subtle side to hypoxia inducible factor (HIFα) regulation , 2003 .

[42]  Moon-Kyoung Bae,et al.  Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation , 2002, Cell.

[43]  S. Safe,et al.  Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in ZR-75 breast cancer cells. , 2002, Molecular endocrinology.

[44]  G. Semenza.  Signal transduction to hypoxia-inducible factor 1. , 2002, Biochemical pharmacology.

[45]  Adrian L. Harris,et al.  Association of hypoxia‐inducible factors 1α and 2α with activated angiogenic pathways and prognosis in patients with endometrial carcinoma , 2002 .

[46]  D. Peet,et al.  FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. , 2002, Genes & development.

[47]  M. Schindl,et al.  Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  L. Poellinger,et al.  Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[49]  A. Harris,et al.  Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. , 2002, Cancer research.

[50]  Y. M. Lee,et al.  Jab1 Interacts Directly with HIF-1α and Regulates Its Stability* , 2002, The Journal of Biological Chemistry.

[51]  S. McKnight,et al.  A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF , 2001, Science.

[52]  J. Kurebayashi,et al.  Hypoxia Reduces Hormone Responsiveness of Human Breast Cancer Cells , 2001, Japanese journal of cancer research : Gann.

[53]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  M. Schindl,et al.  Expression of hypoxia‐inducible factor–1α in oligodendrogliomas , 2001 .

[55]  I. Ellis,et al.  Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[56]  A. Harris,et al.  Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. , 2000, Cancer research.

[57]  M. Schindl,et al.  Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. , 2000, Cancer research.

[58]  Eamonn R. Maher,et al.  Hypoxia Inducible Factor-α Binding and Ubiquitylation by the von Hippel-Lindau Tumor Suppressor Protein* , 2000, The Journal of Biological Chemistry.

[59]  L. Poellinger,et al.  Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein , 2000, The EMBO journal.

[60]  E. Petricoin,et al.  Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines , 2000, Electrophoresis.

[61]  M. Volm,et al.  Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. , 2000, Anticancer research.

[62]  A. Harris,et al.  The macrophage – a novel system to deliver gene therapy to pathological hypoxia , 2000, Gene Therapy.

[63]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[64]  J. Pouysségur,et al.  p42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1α (HIF-1α) and Enhance the Transcriptional Activity of HIF-1* , 1999, The Journal of Biological Chemistry.

[65]  J. Celis,et al.  Short‐term culturing of low‐grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities , 1999, Electrophoresis.

[66]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[67]  Jessica Lo,et al.  HIF‐1α is required for solid tumor formation and embryonic vascularization , 1998 .

[68]  M. Gassmann,et al.  Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. , 1998, Genes & development.

[69]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[70]  H. Tsuda.  HER-2 (c-erbB-2) test update: Present status and problems , 2006, Breast cancer.

[71]  Ian O Ellis,et al.  Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis , 2005, Modern Pathology.

[72]  J. Pouysségur,et al.  Signalling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. , 2005, Cellular signalling.

[73]  A. Howell,et al.  Consensus Statement : Prevention of Flexible , 2005 .

[74]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[75]  P Lambin,et al.  Hypoxia as a target for combined modality treatments. , 2002, European journal of cancer.